Novogen Develops New Class Of Drugs
Edison | Jul 14, 2015 02:50AM ET
Promising anti-cancer drugs head to the clinic
Novogen Ltd (NASDAQ:NVGN) is developing two groups of anti-cancer compounds that have shown a great deal of promise in preclinical studies. Its super-benzopyran drugs are highly potent against cancer stem cells that are resistant to standard chemotherapy drugs, both in vitro and in animal models. Its lead anti-tropomyosin dug, Anisina, shows strong synergy with standard-ofcare anti-mitotic vinca alkaloid drugs. The company is well-funded, having raised ~$26m in the past two months, and is on track to have its three lead anti-cancer drugs in clinical trials by mid-2016. Its base case valuation is $126m, or $7.45 per ADR (undiluted).
Super-benzopyrans: Killing cancer stem cells
Novogen has developed a new class of drugs that it terms super-benzopyrans. These have shown high potency against cells from a wide range of cancers and have outperformed currently-marketed drugs and drugs in development by big pharma in an ovarian cancer stem cell animal model developed by Yale University. Lead super-benzopyran drug Cantrixil will enter clinical trials in late-stage cancer patients with malignant ascites in late 2015/early 2016, followed by Trilexium in solid tumors in mid-2016. Trilexium shows particular potency in preclinical models of prostate cancer, melanoma and brain cancer.
Anti-tropomyosins: Synergy with anti-mitotics
Novogen will also enter the clinic in 2016 with anti-tropomyosin (ATM) drug Anisina. ATMs target micro filaments, one of the two main components of the cell cytoskeleton. ATMs combine synergistically with anti-mitotic drugs that target microtubules – the other major component of the cell cytoskeleton. Combining Anisina with the anti-mitotic vinca alkaloid vincristine increased the potency of vincristine 20-fold. Anisina will initially focus on melanoma, prostate cancer and neuroblastoma.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.